Skip to main content
All lobbying filings

NOVOCURE INC.

Lobbying for NOVOCURE INC.

 Filing 4th Quarter - Report
4th Quarter (Oct 1 - Dec 31) 2025 · Pennsylvania · House · Senate · $110,000.00 expenses · posted Jan 17, 2026

Official filing document

 Bills named in this filing 2
  • HR 5343
    Ensuring Patient Access to Critical Breakthrough Products Act
  • S 1717
    Ensuring Patient Access to Critical Breakthrough Products Act of 2025
 Lobbying activity 2
Medicare/Medicaid

General Medicare Issues. H.R.5343/S.1717 - Ensuring Patient Access to Critical Breakthrough Products Act of 2025.

Tariff (miscellaneous tariff bills)

Tariff issues, specifically related to medical device 232.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem